Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Blanchette

Showing results (11-20 of 76) with videos related to

Pageof 8
Sort By:
Journal of Medical Economics|October 16, 2009
Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPDAnand A Dalal, Hans Petersen, Linda Simoni-Wastila, et al.
The American Journal of Managed Care|July 10, 2008
Economic assessment of initial maintenance therapy for chronic obstructive pulmonary diseaseManabu Akazawa, D Courtney Hayflinger, Richard H Stanford, et al.
Current Medical Research and Opinion|July 23, 2009
Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured populationXin Ye, Benjamin Gutierrez, Victoria Zarotsky, et al.
Annals of Epidemiology|February 12, 2008
A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging populationChristopher M Blanchette, Linda Simoni-Wastila, Ilene H Zuckerman, et al.
Journal of Managed Care Pharmacy : JMCP|March 12, 2008
Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage populationChristopher M Blanchette, Benjamin Gutierrez, Caron Ory, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|March 27, 2010
The role of combination inhaled corticosteroid/long-acting beta-agonist therapy in COPD managementDouglas W Mapel, Judith S Hurley, Anand A Dalal, et al.
BMC Surgery|August 17, 2014
A cross-sectional retrospective analysis of the regionalization of complex surgeryJames Studnicki, Christopher Craver, Christopher M Blanchette, et al.
Drugs in Context|August 20, 2016
Evaluating cost benefits of combination therapies for advanced melanomaIvar S Jensen, Emily Zacherle, Christopher M Blanchette, et al.
Health Services Research|March 29, 2008
Drug use patterns in severely mentally ill Medicare beneficiaries: impact of discontinuities in drug coverageLinda Simoni-Wastila, Ilene H Zuckerman, Thomas Shaffer, et al.
American Health & Drug Benefits|January 8, 2020
Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United StatesMichael C Runken, Joshua M Noone, Christopher M Blanchette, et al.
Pageof 8

Showing results (11-20 of 76) with videos related to

Sort By:
Pageof 8
Journal of Medical Economics|October 16, 2009
Healthcare costs associated with initial maintenance therapy with fluticasone propionate 250 μg/salmeterol 50 μg combination versus anticholinergic bronchodilators in elderly US Medicare-eligible beneficiaries with COPDAnand A Dalal, Hans Petersen, Linda Simoni-Wastila, et al.
The American Journal of Managed Care|July 10, 2008
Economic assessment of initial maintenance therapy for chronic obstructive pulmonary diseaseManabu Akazawa, D Courtney Hayflinger, Richard H Stanford, et al.
Current Medical Research and Opinion|July 23, 2009
Appropriate use of inhaled corticosteroid and long-acting beta(2)-adrenergic agonist combination therapy among asthma patients in a US commercially insured populationXin Ye, Benjamin Gutierrez, Victoria Zarotsky, et al.
Annals of Epidemiology|February 12, 2008
A secondary analysis of a duration response association between selective serotonin reuptake inhibitor use and the risk of acute myocardial infarction in the aging populationChristopher M Blanchette, Linda Simoni-Wastila, Ilene H Zuckerman, et al.
Journal of Managed Care Pharmacy : JMCP|March 12, 2008
Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage populationChristopher M Blanchette, Benjamin Gutierrez, Caron Ory, et al.
Primary Care Respiratory Journal : Journal of the General Practice Airways Group|March 27, 2010
The role of combination inhaled corticosteroid/long-acting beta-agonist therapy in COPD managementDouglas W Mapel, Judith S Hurley, Anand A Dalal, et al.
BMC Surgery|August 17, 2014
A cross-sectional retrospective analysis of the regionalization of complex surgeryJames Studnicki, Christopher Craver, Christopher M Blanchette, et al.
Drugs in Context|August 20, 2016
Evaluating cost benefits of combination therapies for advanced melanomaIvar S Jensen, Emily Zacherle, Christopher M Blanchette, et al.
Health Services Research|March 29, 2008
Drug use patterns in severely mentally ill Medicare beneficiaries: impact of discontinuities in drug coverageLinda Simoni-Wastila, Ilene H Zuckerman, Thomas Shaffer, et al.
American Health & Drug Benefits|January 8, 2020
Differences in Patient Demographics and Healthcare Costs of Patients with PIDD Receiving Intravenous or Subcutaneous Immunoglobulin Therapies in the United StatesMichael C Runken, Joshua M Noone, Christopher M Blanchette, et al.
Pageof 8